Moreover, sphingolipid metabolism has been found to be dysregulated in many human diseases, including cancer, inflammation, atherosclerosis and asthma [43], with therapies targeting S1P signalling being effective at controlling disease in MS patients [25, 26]. Here, MBTPS1 is linked to atherosclerosis.